CA2733250C - Compounds as kinase inhibitors - Google Patents

Compounds as kinase inhibitors Download PDF

Info

Publication number
CA2733250C
CA2733250C CA2733250A CA2733250A CA2733250C CA 2733250 C CA2733250 C CA 2733250C CA 2733250 A CA2733250 A CA 2733250A CA 2733250 A CA2733250 A CA 2733250A CA 2733250 C CA2733250 C CA 2733250C
Authority
CA
Canada
Prior art keywords
yloxy
methoxy
azaspiro
heptan
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2733250A
Other languages
English (en)
French (fr)
Other versions
CA2733250A1 (en
Inventor
Guoqing Paul Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADVENCHEN LABORATORIES LLC
Original Assignee
ADVENCHEN LABORATORIES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADVENCHEN LABORATORIES LLC filed Critical ADVENCHEN LABORATORIES LLC
Publication of CA2733250A1 publication Critical patent/CA2733250A1/en
Application granted granted Critical
Publication of CA2733250C publication Critical patent/CA2733250C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2733250A 2008-08-19 2009-08-13 Compounds as kinase inhibitors Active CA2733250C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8990808P 2008-08-19 2008-08-19
US61/089,908 2008-08-19
US12/540,300 2009-08-12
US12/540,300 US8211911B2 (en) 2008-08-19 2009-08-12 Compounds as kinase inhibitors
PCT/US2009/053779 WO2010021918A1 (en) 2008-08-19 2009-08-13 Compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
CA2733250A1 CA2733250A1 (en) 2010-02-25
CA2733250C true CA2733250C (en) 2016-06-21

Family

ID=41696956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2733250A Active CA2733250C (en) 2008-08-19 2009-08-13 Compounds as kinase inhibitors

Country Status (13)

Country Link
US (1) US8211911B2 (pt)
EP (1) EP2312950B1 (pt)
JP (1) JP5585892B2 (pt)
KR (1) KR101727757B1 (pt)
CN (1) CN102159078B (pt)
AU (1) AU2009282962B2 (pt)
BR (1) BRPI0912475B8 (pt)
CA (1) CA2733250C (pt)
ES (1) ES2617678T3 (pt)
IL (1) IL210573A (pt)
MX (1) MX2010011813A (pt)
NZ (1) NZ590954A (pt)
WO (1) WO2010021918A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) * 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
CN110357856B (zh) * 2018-04-09 2021-02-26 新发药业有限公司 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法
CN112469711A (zh) * 2018-07-24 2021-03-09 正大天晴药业集团股份有限公司 一种喹啉衍生物的合成方法
CN108864050B (zh) * 2018-07-25 2019-12-10 上海博璞诺科技发展有限公司 一种合成安罗替尼及其盐酸盐的方法
CN113045559B (zh) * 2021-03-15 2022-05-20 贵州医科大学 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
ES2351699T3 (es) * 1999-02-10 2011-02-09 Astrazeneca Ab Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos.
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
KR100942073B1 (ko) 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
EP1660503A1 (en) 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
CA2551508C (en) 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
AU2005207946A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
EA011402B1 (ru) * 2004-01-23 2009-02-27 Эмджен Инк. Азотсодержащие гетероциклические производные и их фармацевтические применения
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
US20080268460A1 (en) 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
EP1915368A1 (en) 2005-08-08 2008-04-30 Pfizer, Inc. Salts and polymorphs of a vergf-r inhibitor
US7977346B2 (en) * 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors

Also Published As

Publication number Publication date
AU2009282962B2 (en) 2015-10-08
EP2312950A4 (en) 2012-10-24
CA2733250A1 (en) 2010-02-25
EP2312950A1 (en) 2011-04-27
JP2012500269A (ja) 2012-01-05
WO2010021918A8 (en) 2011-01-27
EP2312950B1 (en) 2016-11-30
BRPI0912475B1 (pt) 2020-12-29
NZ590954A (en) 2012-11-30
ES2617678T3 (es) 2017-06-19
BRPI0912475A8 (pt) 2018-03-20
KR20110044749A (ko) 2011-04-29
IL210573A0 (en) 2011-03-31
US8211911B2 (en) 2012-07-03
AU2009282962A8 (en) 2011-11-10
WO2010021918A1 (en) 2010-02-25
IL210573A (en) 2016-05-31
KR101727757B1 (ko) 2017-04-17
AU2009282962A1 (en) 2010-02-25
MX2010011813A (es) 2010-12-01
BRPI0912475B8 (pt) 2021-05-25
JP5585892B2 (ja) 2014-09-10
CN102159078A (zh) 2011-08-17
CN102159078B (zh) 2014-05-21
BRPI0912475A2 (pt) 2018-01-09
US20100048599A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
CA2733250C (en) Compounds as kinase inhibitors
CA2681005C (en) Spiro substituted compounds as angiogenesis inhibitors
CA2709220C (en) Spiro substituted compounds as angiogenesis inhibitors
AU2007205962B2 (en) Spiro compounds and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140811